Skip to main content
OpenTrials
Completed

NCT Number: NCT03120975

Computerized Antibiotic Stewardship Study

Prescribing antibiotics frequently poses problems in practice, since patients don't always receive the right dosage of the right antibiotic for the right period of time. This promotes the emergence and spread of antibiotic resistance. The investigators of this trial aim to develop a system designed to help doctors to use antibiotics more appropriately. Under COMPASS (COMPuterized Antibiotic Stewardship Study), doctors in three Swiss hospitals will receive tips on the use of antibiotics that are integrated directly into electronic health record and will also be given regular feedback on their use of antibiotics. Parallel to this, data on the antimicrobial prescription practices of a control group which is not using the system will be collected.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ente Ospedaliera Cantonale - Ospedale San Giovanni, Bellinzona, Canton Ticino, Switzerland

Loading trial locations.

About this study

Inappropriate use of antimicrobials favours the spread and emergence of antimicrobial resistance and other adverse patient outcomes. Antimicrobial stewardship (AMS) programs aim to promote the appropriate use of antimicrobials. Most AMS interventions are based on manual, personalized peer review of antibiotic prescriptions by specialists and are therefore time and resource intensive. Informatics based, computerized approaches to AMS are a promising way to "automatize" AMS, but there have been only few randomized controlled trials analysing their effectiveness in the hospital setting.

The primary research question of this study is whether a multi-modal, computerized antibiotic stewardship intervention (I) reduces overall antibiotic exposure (O) in adult patients hospitalized in acute-care wards of secondary and tertiary care centers (P) compared to no such intervention ("standard-of- care") (C) over a one year time period (T) (the letters refer to the corresponding constituents of the PICOT framework).

The primary objective of the study is to use the methodological rigor of a parallel group, cluster-randomized, controlled superiority trial in three Swiss hospitals to answer the primary research question. Secondary objectives are to assess the impact of the intervention on quality of antibiotic use, patient, microbiologic and economic outcomes.

The primary outcome will be the difference in overall systemic antibiotic use measured in days of therapy (DOT) per admission based on administration data recorded in the electronic health record (EHR) over the whole intervention period. Secondary outcomes will include qualitative and quantitative antimicrobial use indicators (including non-HIV antivirals and antifungals), economic outcomes and key clinical and microbiologic indicators and patient safety indicators such as changes in readmission rates, need for intensive care and mortality.

The study hypothesis is that the multimodal intervention is superior to standard-of-care regarding the primary outcome, i.e. that the intervention leads to a statistically significant reduction in overall antibiotic use expressed as days of therapy per admission compared to no such intervention ("standard-of-care" antibiotic stewardship).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CLUSTER (WARD) LEVEL

  • Acute-care wards with at least 150 admissions/year
  • Use of a computerized physician order entry system (CPOE)

PHYSICIAN LEVEL * All physicians involved in antibiotic prescribing decisions in the participating wards

PATIENT LEVEL

  • All patients hospitalized in the participating wards

Exclusion criteria

CLUSTER (WARD) LEVEL

  • Emergency room
  • Outpatient clinics
  • Overflow wards
  • Absence of a matchable wards with regard to specialty and baseline antibiotic use
  • Hematopoietic stem cell

PHYSICIAN LEVEL * None

PATIENT LEVEL

  • None

Treatment and study plan

Computerized decision support and audit & feedback

Other
  • suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system
  • mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment
  • suggestion of standard antimicrobial treatment duration according to indication

Audit & Feedback

Other
  • regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)

Standard antibiotic stewardship

Other
  • Infectious diseases consultation "on demand"
  • Review of positive blood cultures
  • Availability of a antibiotic use guidelines (on paper and as PDF)

Primary outcomes

  1. Days of therapy (DOT)/admission

    Time frame: 12 months

    Overall days of therapy of antibiotics per admission on the ward level

Secondary outcomes

  1. Days of therapy(DOT)/100 patient days

    Time frame: 12 months

    Overall days of therapy per 100 patient days (PD) on the ward level

  2. Defined daily doses (DDD)/100 patient days (PD) and per admission

    Time frame: 12 months

    Overall defined daily doses per 100 patient days and admission on the ward level

  3. Antimicrobial days (AD) per 100 PD and per admission

    Time frame: 12 months

    Length of therapy per 100 PD and per admission

  4. Days per treatment period overall

    Time frame: 12 months

    Overall days per treatment period. A treatment period is defined as antibiotic treatment not interrupted by more than one calendar day or discharge.

  5. 30 day-mortality

    Time frame: 12 months

    All cause 30 day-mortality

  6. In-hospital mortality

    Time frame: 12 months

    All-cause in-hospital mortality

  7. Hospital readmission within 30 days of discharge

    Time frame: 12 months

    Unplanned hospital readmission within 30 days of discharge

  8. Hospital length of stay (LOS)

    Time frame: 12 months

    Hospital length of stay

  9. ICU transfer

    Time frame: 12 months

    % of admissions transferred to ICU after initial non-ICU admission

  10. Guideline compliance

    Time frame: 12 months

    Proportion of patients treated in compliance with facility-based guideline

  11. De-escalation

    Time frame: 12 months

    Proportion of patients with "de-escalation" and "escalation" of antibiotic therapy by calendar day 4 of treatment

  12. IV-oral switch

    Time frame: 12 months

    Proportion of patients converted from intravenous to oral therapy between days 4 and 7

  13. appropriate diagnostic exams

    Time frame: 12 months

    proportion of patients with appropriate diagnostic exams

  14. Incidence of Clostridium difficile infections (CDI)

    Time frame: 12 months

    Incidence of healthcare-facility onset Clostridium difficile infection denominated by 10 000 PD and admission

  15. Incidence of multidrug-resistant organisms (MDRO)

    Time frame: 12 months

    Incidence of clinical cultures with multidrug resistant organisms (methicillin-resistant Staphylococcus aureus (MRSA), Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E), carbapenemase-producing Enterobacteriaceae (CPE), vancomycin-resistant enterococci (VRE), multidrug resistant P. aeruginosa) denominated per 1000 PD and admissions

  16. User satisfaction

    Time frame: 12 months

    User satisfaction with the system

  17. Costs of administered antimicrobials

    Time frame: 12 months

    Costs of administered antimicrobials (overall and by class) per admission and per admission receiving antibiotics

  18. costs of the intervention

    Time frame: 12 months

    total costs of the intervention

  19. number of infectious diseases consultations

    Time frame: 12 months

    proportion of patients with infectious diseases consultation

  20. Days per treatment period for community acquired pneumonia

    Time frame: 12 months

    A treatment period is defined as antibiotic treatment not interrupted by more than one calendar day or discharge.

  21. Days per treatment period for upper urinary tract infection

    Time frame: 12 months

    A treatment period is defined as antibiotic treatment not interrupted by more than one calendar day or discharge.

Sponsors and collaborators

Lead sponsor

Benedikt Huttner

Other

Collaborators

  • Ente Ospedaliero Cantonale, Ticino, Switzerland
  • Swiss National Science Foundation
  • University of Geneva, Switzerland

Registry information

Official study title

Improvement of Antibiotic Use in Hospitals Through Pragmatic, Multifaceted, Computerized Interventions: a Multicentre, Cluster-randomized Trial - COMPASS Study (COMPuterized Antibiotic Stewardship Study)

Acronym: COMPASS

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Apr 19, 2017
Registry last updated
Nov 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.